Table 2. Functional assessment and echocardiographic indicators at week 0 and 24 in the macitentan monotherapy group.
| Parameters | Baseline | After treatment | Statistic | P |
|---|---|---|---|---|
| WHO-FC | Z=−2.33 | 0.02 | ||
| I | 0 | 2 | ||
| II | 2 | 4 | ||
| III | 6 | 3 | ||
| IV | 1 | 0 | ||
| 6MWD (m) | 280.00 (185.00, 362.50) | 450.00 (327.50, 482.50) | Z=−2.67 | 0.008 |
| NT-proBNP (mmHg) | 1,605.00 (719.45, 2,275.05) | 328.60 (55.19, 658.60) | Z=−2.67 | 0.008 |
| RVD (mm) | 43.78±8.35 | 36.89±6.83 | t=1.98 | 0.08 |
| RAD (mm) | 44.78±8.79 | 37.89±6.23 | t=2.03 | 0.08 |
| AAO (mm) | 33.00±4.06 | 33.33±4.18 | t=−0.76 | 0.47 |
| LVEDd (mm) | 45.00 (35.00, 61.00) | 48.00 (41.50, 51.00) | Z=−1.01 | 0.31 |
| sPAP (mmHg) | 76.11±20.67 | 47.22±28.06 | t=6.20 | <0.001 |
| TRPG (mmHg) | 72.11±21.35 | 44.11±28.62 | t=5.60 | 0.001 |
| TAPSE (mm) | 16.28±2.59 | 18.61±2.29 | t=−3.04 | 0.02 |
| ALT (U/L) | 23.60 (10.10, 32.25) | 14.50 (8.10, 28.00) | Z=−0.89 | 0.37 |
| AST (U/L) | 19.00 (17.45, 29.80) | 20.70 (17.85, 25.60) | Z=0.001 | >0.99 |
| Scr (µmol/L) | 59.80 (54.20, 64.35) | 63.00 (46.75, 79.40) | Z=−1.01 | 0.31 |
| Hb (g/L) | 130.00 (115.50, 144.00) | 110.00 (93.50, 142.00) | Z=−1.24 | 0.21 |
Data are presented as numbers, mean ± standard deviation or median (interquartile range). WHO-FC, World Health Organization functional class; 6MWD, 6-minute walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide; RVD, right ventricular diameter; RAD, right atrial diameter; AAO, ascending aortic root inner diameter; LVEDd, left ventricular end-diastolic diameter; sPAP, systolic pulmonary artery pressure; TRPG, tricuspid regurgitation pressure gradient; TAPSE, tricuspid annular plane systolic excursion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Scr, serum creatinine; Hb, hemoglobin.